Fulgent Genetics, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 trading arrangements
During the quarter ended December 31, 2025, none of our directors or officers, as each term is defined in Rule 16a-1(f) of the Exchange Act, adopted orterminated “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, except as follows:
On November 25, 2025, Hanlin Gao, our Chief Scientific Officer and Laboratory Director, entered into a Rule 10b5-1 sales plan, or the Gao Sales Plan, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. The Gao 10b5-1 Sales Plan, which has a term that expires on January 31, 2027, provides for the sale of up to 100,000 shares of our common stock.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.